Table 2.
The assessment of SARS‐CoV‐2 RT‐PCR results of NPS and DTS samples pairs from 29 confirmed patients with COVID‐19 (n = 61)
| Patient | Sample pair | SARS‐CoV‐2 RT‐PCR (C t a value) | Assessment | |
|---|---|---|---|---|
| NPSb | DTSc | |||
| AE | 20 | P (21.3) | P (25.4) | Concordant |
| 21 | P (25.9) | P (31.3) | Concordant | |
| 22 | P (29.3) | P (33.2) | Concordant | |
| 23 | P (32.4) | P (33.0) | Concordant | |
| 24 | P (33.3) | P (34.0) | Concordant | |
| 25 | N (0) | P (36.7) | Discordant | |
| AB | 8 | P (22.3) | P (19.9) | Concordant |
| 9 | P (28.8) | P (24.6) | Concordant | |
| 10 | P (28.4) | P (27.7) | Concordant | |
| 11 | P (27.7) | P (25.2) | Concordant | |
| 12 | P (33.1) | N (0) | Discordant | |
| 13 | N (0) | P (35.8) | Discordant | |
| AJ | 34 | P (29.6) | P (23.5) | Concordant |
| 35 | N (0) | P (36.4) | Discordant | |
| 36 | N (0) | P (36.0) | Discordant | |
| 37 | N (0) | N (0) | Concordant | |
| BC | 77 | P (27.6) | P (31.5) | Concordant |
| 78 | P (34.6) | N (0) | Discordant | |
| 79 | N (0) | P (36.1) | Discordant | |
| 80 | N (0) | P (37.9) | Discordant | |
| AN | 45 | P (35.6) | P (32.4) | Concordant |
| 46 | N (0) | P (35.3) | Discordant | |
| 47 | P (33.9) | N (0) | Discordant | |
| BB | 75 | N (0) | P (33.7) | Discordant |
| 76 | P (34.5) | N (0) | Discordant | |
| AY | 70 | P (23.9) | N (0) | Discordant |
| 71 | P (30.6) | N (0) | Discordant | |
| AV | 59 | N (0) | P (35.4) | Discordant |
| 60 | N (0) | P (36.0) | Discordant | |
| BA | 73 | P (21.2) | P (30.8) | Concordant |
| 74 | P (35.9) | N (0) | Discordant | |
| AC | 14 | N (0) | P (37.6) | Discordant |
| AO | 48 | N (0) | P (33.8) | Discordant |
| AZ | 72 | N (0) | P (35.6) | Discordant |
| AI | 30 | P (32.8) | P (34.5) | Concordant |
| 31 | P (36.4) | P (32.1) | Concordant | |
| 32 | N (0) | N (0) | Concordant | |
| 33 | P (37.4) | P (33.5) | Concordant | |
| BH | 90 | P (22.1) | P (27.9) | Concordant |
| 91 | P (28.4) | P (32.2) | Concordant | |
| 92 | P (33.9) | P (35.4) | Concordant | |
| AX | 67 | P (22.7) | P (27.0) | Concordant |
| 68 | P (31.7) | P (30.1) | Concordant | |
| AW | 65 | P (19.8) | P (32.2) | Concordant |
| 66 | N (0) | N (0) | Concordant | |
| AP | 51 | P (19.7) | P (22.3) | Concordant |
| 52 | P (25.7) | P (25.7) | Concordant | |
| AR | 54 | P (17.4) | P (20.0) | Concordant |
| 55 | P (29.6) | P (32.2) | Concordant | |
| BE | 82 | P (32.6) | P (32.5) | Concordant |
| 83 | P (34.5) | P (35.9) | Concordant | |
| AH | 28 | P (24.1) | P (22.6) | Concordant |
| AS | 56 | P (18.2) | P (22.3) | Concordant |
| AT | 57 | P (23.9) | P (21.2) | Concordant |
| AU | 58 | P (34.3) | P (34.0) | Concordant |
| AM | 42 | P (27.9) | P (30.2) | Concordant |
| AF | 26 | P (17.0) | P (21.3) | Concordant |
| AA | 1 | P (32.0) | P (25.9) | Concordant |
| BG | 89 | P (19.6) | P (22.7) | Concordant |
| AQ | 53 | P (26.5) | P (30.6) | Concordant |
| BF | 84 | P (25.2) | P (31.0) | Concordant |
Abbreviations: COVID‐19, coronavirus disease 2019; DTS, deep throat saliva; NPS, Nasopharyngeal swabs; RT‐PCR, reverse transcription‐polymerase chain reaction; SARS‐CoV2, severe acute respiratory syndrome coronavirus 2.
a
Cycle threshold.
b
Nasopharyngeal swab.
c
Deep throat saliva.